Putting placebo-controlled trials in developing countries to the interpersonal justifiability test.

Area of Science:

• Bioethics
• Global Health Ethics
• Clinical Trial Ethics

Background:

• Placebo-controlled trials in developing countries raise ethical concerns when effective treatments are unavailable locally.
• Such trials are permissible in nations with higher standards of care but not where standards are low.

Purpose of the Study:

• To analyze the ethical permissibility of placebo-controlled trials in developing countries.
• To explain moral intuitions regarding these trials, particularly concerning the beneficiaries of the research.
• To propose a framework for evaluating the ethical justification of such research.

Main Methods:

• Utilizing GA Cohen's concept of interpersonal justifiability to assess ethical claims.
• Examining the role of pharmaceutical corporations in healthcare inequalities between developing and developed nations.
• Reviewing empirical evidence on pharmaceutical corporations' adherence to ethical standards.

Main Results:

• Placebo-controlled trials in developing nations are ethically problematic because they are not comprehensively justified.
• Healthcare inequalities, partly attributable to pharmaceutical corporations, render these trials ethically questionable.
• Pharmaceutical corporations often fail the interpersonal justifiability test.

Conclusions:

• The interpersonal justifiability framework provides a nuanced explanation for ethical intuitions about research in developing countries.
• This framework can help assess the ethical permissibility of research involving vulnerable populations, even within developed nations.
• Greater accountability for pharmaceutical corporations is needed to ensure ethical global health research.